Organon signs agreements in Ireland and Brazil:
This article was originally published in Clinica
Executive Summary
Organon Teknika is to distribute Epitope's OraQuick oral fluid rapid test for HIV in Ireland and also Visible Genetics' OpenGene and GeneKits in Brazil. The Irish agreement calls for Organon to collaborate on the final product development and manufacture pre-production lots. The Brazilian deal is a four-year agreement guaranteeing Visible Genetics a minimum annual revenue. The companies say that the deal will open the Latin American market to drug resistance testing.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.